More Articles

Draft guide on monitoring medical literature released for public consultation Guidelines | Posted 13/06/2014

On 5 June 2014, the European Medicines Agency (EMA) released a draft guide on the monitoring of medical literature and the entry of relevant information into the EudraVigilance database. The draft...

The global biologicals market Reports | Posted 13/06/2014

Global spending on medicines is expected to reach the US$1 trillion threshold in 2014 and rise to US$1.2 trillion by 2017.

European regulators give green light to Ranbaxy plant Generics/General | Posted 13/06/2014

In what comes as good news for generics maker Ranbaxy, European Regulators have cleared the company’s Toansa plant.

Oncobiologics and IPCA create biosimilars alliance Biosimilars/News | Posted 13/06/2014

US-based Oncobiologics announced on 2 June 2014 the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibodies with Indian generics m...

First generic celecoxib approved by FDA Generics/News | Posted 13/06/2014

The US Food and Drug Administration (FDA) announced on 30 May 2014 that it had approved the first generic versions of celecoxib capsules.

Impact of price cuts on spending on hyperlipidaemic drugs in South Korea Generics/Research | Posted 06/06/2014

Rapidly increasing pharmaceutical expenditures have become a constant challenge to the sustainability of healthcare systems across countries including Korea.

Top 8 blockbuster biologicals 2013 Biosimilars/General | Posted 06/06/2014

The top three best-selling drugs during 2013 were biologicals. All three best-sellers are indicated for the treatment of arthritis, and include Abbott’s Humira (adalimumab), Merck’s Remicade (infli...

Europe–Japan cooperation on generics and biosimilars regulation Policies & Legislation | Posted 06/06/2014

Japanese and European generics groups have met to discuss increase regulatory cooperation between the two regions.